Research programme: neuropsychiatric disorder therapies - Roche/PsychoGenics

Drug Profile

Research programme: neuropsychiatric disorder therapies - Roche/PsychoGenics

Latest Information Update: 24 Apr 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PsychoGenics; Roche
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Neurological disorders; Psychiatric disorders

Most Recent Events

  • 24 Apr 2014 PsychoGenics and Roche extend their collaborative agreement for neuropsychiatric disorder therapies for an additional five years
  • 21 Nov 2011 Early-stage research is ongoing in the US
  • 16 Nov 2011 Roche exercises its option to develop a drug candidate from this research programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top